Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 27 abril 2025
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex, Arthritis Research & Therapy
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial, Trials
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Temporal trends in adverse pregnancy outcomes in axial spondyloarthritis in Sweden: a cohort study - The Lancet Rheumatology
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison - Document - Gale OneFile: Health and Medicine
Recomendado para você
você pode gostar

© 2014-2025 likytut.eu. All rights reserved.